Report cover image

Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published May 30, 2022
Length 76 Pages
SKU # GBDT17290804

Description

Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Neuroendocrine tumors therapeutics.

Synopsis
  • In 2022, diagnosed prevalence of Neuroendocrine tumors will reach to 689,000 cases across the 16 countries covered in GlobalData’s epidemiology forecast.
  • There are eight leading marketed drugs for the treatment of Neuroendocrine tumors. Pfizer, Novartis, and Hutchison are key players in the disease space.
  • R&D activity in Neuroendocrine tumors space is considerable globally, with 11 products in Phase III development.
  • Academic sponsors dominate clinical trial development in Neuroendocrine tumors, with Germany emerging as the key country for conducting late-stage clinical trials in Neuroendocrine tumors.
  • Deals involving strategic alliances of Neuroendocrine tumors assets are the most common type globally.
  • No commercial launch is expected for Neuroendocrine tumors in the next 18 months.
Scope

GlobalData’s Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Neuroendocrine tumors market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine tumors market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

76 Pages
  • Report Scope
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Diagnosed Prevalent Cases of NET in 2022 and 2027
  • Treatment Overview
  • Treatment Guidelines
    • Marketed Drugs - Leading Marketed Drugs in NET
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile: Ipsen's Somatuline
    • Marketed Drug Profile: Novartis's Sandostatin
    • Marketed Drug Profile: Novartis's Sandostatin LAR
    • Marketed Drug Profile: Novartis's Afinitor
    • Marketed Drug Profile: Hutchison's Sulanda
    • Marketed Drug Profile: Roche's Rozlytrek
    • Marketed Drug Profile: Pfizer's Sutent
    • Marketed Drug Profile: Advanced Accelerator Applications/Novartis's Lutathera
    • Marketed Drug Profile: Progenics Pharmaceuticals's Azedra
    • Pipeline Drugs Overview - Phase III Pipeline Drugs in NET
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Oncology and in NET
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in NET
    • Clinical Trials in NET - Historical Overview
    • Clinical Trials in NET - Overview by Phase
    • Clinical Trials in NET - Overview by Status
    • Clinical Trials in NET - Overview by Phase for Ongoing and Planned Trial
    • Clinical Trials in NET - Trials with a Virtual Component
    • Clinical Trials in NET - Geographic Overview
    • Clinical Trials in NET - Single-Country and Multinational Trials by Region
    • Clinical Trials in NET - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in NET - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in NET - Overview by Endpoint Status
    • Clinical Trials in NET - Overview by Race and Ethnicity
    • Clinical Trials in NET - Enrollment Data
    • Clinical Trials in NET - Overview of Sites by Geography
    • Clinical Trials in NET - Top 20 Countries for Trial Sites
    • Clinical Trials in NET - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for NET
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in NET by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in NET
    • Commercial Assessment - Key Market Players in NET
    • Future Market Catalysts - Upcoming Market Catalysts in NET
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
    • Contact Us - A Global Network of Offices

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us